Lv4
510 积分 2025-05-29 加入
Disease context dictates the cellular targets of IL-17 in inflammatory skin disease
8天前
已完结
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
30天前
已完结
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
30天前
已完结
Selective blockade of interleukin 6 trans-signaling depresses atrial fibrillation
1个月前
已完结
Role of the IL-33/ST2 axis in cigarette smoke-induced airways remodelling in chronic obstructive pulmonary disease
1个月前
已完结
Dual Blockade of Interleukin-1β and Interleukin-17A Reduces Murine Arthritis Pathogenesis but Also Leads to Spontaneous Skin Infections in Nonhuman Primates
1个月前
已完结
Blocking IL-6 down-regulates PD-L1 expression and mitigates pulmonary fibrosis by inhibiting the STAT3 signaling pathway
1个月前
已完结
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimzumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled dose–escalation study
2个月前
已完结
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
2个月前
已完结
皖公网安备34019202002308
